What is Sage Therapeutics?
Founded in 2010 and headquartered in Cambridge, Massachusetts, Sage Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of novel medicines. The company focuses on the central nervous system, targeting significant unmet medical needs through a rigorous scientific approach. Its market position is defined by its ability to bridge the gap between breakthrough laboratory research and scalable clinical applications, supported by a sophisticated network of institutional investors and strategic partners.
How much funding has Sage Therapeutics raised?
Sage Therapeutics has raised a total of $2.2B across 10 funding rounds:
Series B
$20M
Series C
$38M
Stock Offering
$103.5M
Stock Offering
$138M
Stock Offering
$150M
Stock Offering
$175M
Stock Offering
$345M
Stock Offering
$575M
Stock Offering
$575M
Series B (2013): $20M led by ARCH Ventures and Third Rock Ventures
Series C (2014): $38M supported by ARCH Ventures, Third Rock Ventures, OrbiMed, Foresite Capital Management, and EcoR1 Capital Management
Stock Issuance/Offering (2014): $103.5M, investors not publicly disclosed
Stock Issuance/Offering (2015): $138M, investors not publicly disclosed
Stock Issuance/Offering (2016): $150M, investors not publicly disclosed
Stock Issuance/Offering (2016): $175M, investors not publicly disclosed
Stock Issuance/Offering (2017): $345M, investors not publicly disclosed
Stock Issuance/Offering (2018): $575M, investors not publicly disclosed
Stock Issuance/Offering (2019): $575M, investors not publicly disclosed
Key Investors in Sage Therapeutics
Third Rock Ventures
A healthcare venture firm focused on disruptive areas of science and medicine, Third Rock Ventures specializes in launching and building companies that translate bold scientific ideas into successful business enterprises.
ARCH Venture Partners
A leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups to commercialize innovations from academic and corporate research.
OrbiMed
A specialized investment firm focused on the healthcare sector, OrbiMed manages capital across biopharmaceuticals and medical devices, providing deep expertise in life sciences and healthcare business development.
What's next for Sage Therapeutics?
Looking ahead, Sage Therapeutics is positioned to leverage its recent capital influx to accelerate its clinical development programs and strengthen its commercial infrastructure. The company's strategic roadmap emphasizes the advancement of its core therapeutic assets through late-stage trials and regulatory milestones. As the firm scales, the focus will likely shift toward optimizing market access and expanding its portfolio, ensuring that its innovative treatments reach a broader patient demographic. The continued support from top-tier venture capital firms provides the necessary runway to navigate the complexities of the biopharmaceutical landscape and maintain its competitive edge in the development of next-generation neurological therapies.
See full Sage Therapeutics company page
